Grants

Application Procedure

Proposals should be brief, with the project description strictly limited to six pages.  Applications may be submitted at any time during the year, and they are peer-reviewed quickly, with a response within 30 to 90 days. We require a CV from the principal investigator with a letter of support from the senior individual in whose laboratory the study will be carried out.  Please describe in detail the proposed economics of the study (e.g. costs for reagents, labor, equipment, indirect costs, etc.)

Peer Review & Assistance

Proposals will be evaluated by the HHV-6 Foundation’s Scientific Advisory Board, plus selected outside experts, under the direction of the Scientific Director. See Scientific Advisory Board. The Scientific Director and associated experts are also available for ongoing advice once the project has begun and for pre-application assistance. The Scientific Director will review applications for comment in advance if desired, and the Foundation will assist in locating reagents that are difficult to find that might be required. The Foundation has established a Repository of materials that are available for research projects.

Eligibility & Conditions

These grants are available to investigators at established research institutions.  Grants are available to citizens of any country.

Funding for Pilot Research Projects is limited to a maximum of $25,000 in direct costs for one year.  The Foundation will not fund major items of equipment or extensive travel.  The Foundation may add an amount for indirect costs up to 10% of the sum requested by the principal investigator to be paid to the investigator’s institution.

At the termination of the Pilot Research project, the investigator is asked to prepare a detailed report of the findings and account for the expenditures within 30 days.

Acknowledgment

If a manuscript is accepted for publication, the investigator is asked to acknowledge the HHV-6 Foundation’s support with a sentence such as “This investigation was supported by a Pilot Grant from the HHV-6 Foundation.”  We also ask that an advance copy of the manuscript be sent by email to the HHV-6 Foundation’s Scientific Director, after acceptance but before publication.

Studies funded by the HHV-6 Foundation

2011
Efficacy of antiviral drug treatment of HHV-6 infection	Peter Medveczky, University of South Florida
Development of Humanized Rag2-/-gc-/- Mice as a model of HHV-6A infection	Bradford Berges, Brigham Young University
The contribution of neuroinflammatory responses to HHV-6B/HHV-7 infection in the pathogenesis of mesial temporal lobe epilepsy	Jin Mei Li, MD & Dong Zhou, MD, West China Hospital & Sichuan University
HHV-6 in adult and pediatric brain tumors	Michael Scheurer, Dan L. Duncan and Texas Children’s Cancer Centers, Baylor College of Medicine
Prevalence and significance of ciHHV-6 infection in liver transplant recipients	Raymund Razonable, Division of Transplant and Infectious Diseases, Mayo Clinic
2010
Study of Chromosomally Integrated HHV-6 Subjects Prior and Post Valcyte Treatment	Daniel Peterson, MD, Simmaron Research
The role of HHV-6 in pediatric convulsions of unknown cause	Ankrah Lennox-Mac, Department of Microbiology, University of Ghana Medical School
Development of an improved TCID50 assay for HHV-6A	Rasmus Gustafsson, The Karolinska Institute, Sweden
Human Herpesvirus-6, dendritic cells and TH17	Anshu Agrawal, University of California at Irvine
The role of U94/rep gene and TTAGGG telometric repeats of HHV-6 in integration in human chromosomes	Peter Medveczky, University of South Florida
The Functional Characterization of HHV-6/U94 Gene Product	Louis Flamand, Centre Hospital University de Quebec
2009
Anti-HHV-6 activity of the broad antiinfective drug artesunate: investigation of the mode of action	Jens Milbradt & Manfred Marschall, Institute for Clinical and Molecular Virology, Erlangen Medical Center, Germany
Adoptive T cell Immunotherapy to Prevent or Treat HHV-6	Ulrike Gerdeman, Center for Cell & Gene Therapy, Baylor University
XMRV, HHV-6, EBV & Endogenous retroviruses in patients with CFS	Brigitte Huber, Tufts University
2008 and Beyond
HHV-6 Specific CD8+ T cell Responses	Sudhir Gupta, MD, PhD, MACP University of California Irvine, California USA
Development of a Variant-specific, Calibrated Real-time PCR Assay for the Absolute Quantification of HHV-6A and B Nucleic Acids in Clinical Samples	Mauro S. Malnati, MDSan Raffaele Scientific InstituteMilan, Italy  USA
The Human Herpesvirus 6A U45 Gene Product: Role in Immune Dysfunction	Marshall Williams, PhDOhio State University, USA
Variant Specific PCR ELISA	Yi-Wei Tang, MD, PhDVanderbilt University, USA
Determination of the chromosomal integration of the HHV-6 virus in highly seropositive Chronic Fatigue Syndrome patients	Daniel L. Peterson, MD, Sierra Internal Medicine, Nevada, USA
The role of chronic immune stimulation by active  herpesvirus 6 (HHV6) infection/coinfections in immune dysfunction and development of lymphoma	Daniel L. Peterson, MD, Sierra Internal Medicine, Nevada, USA
Investigation of inhibitory effects of the multipotent drug Artesunate against HHV-6	Manfred Marschall, PhDUniversität Erlangen-Nürnberg, Germany
Creation of a humanized CD46 mouse model for HHV6 infection	Claude P. Genain, MDCalifornia Pacific Medical Center Research Institute, San Francisco USA
Study of HHV-6 & EBV in patients with CNS Dysfunction and long-standing fatigue	Jose Montoya, MDStanford University, USA
Use of recombinant viral proteins for the identification of active HHV-6 infection by serological assays.	Louis Flamand, PhD,Universite Laval, Quebec, Canada, USA
Cloning the HHV-6 A and B genome for the identification of genes responsible for pathogenicity	Peter Medveczky, MD, University of South Florida, College of Medicine, USA
A study of incidence of CIHHV-6 in children with congenital infection of HHV-6	Carolyn Hall, MDUniversity of Rochester
Study of HHV-6B in Mesial Temporal Lobe Epilepsy	Nihal De Lanerolle, MD, PhDYale University, MD, PhD
CIHHV-6 FISH analysis	Peter Ambros, PhDChildren’s Cancer Research Institute
HHV-6 activation of HERV K18	Brigitte Huber, PhdTufts University